<p>美国人口老龄化速度比以往任何时候都快，引起了对长寿股的兴趣。到 2030 年，五分之一的美国人将是老年人，而 100 年前这个比例是二十分之一。</p>
<p>因此，旨在针对与年龄相关的基因组变化的 Crispen 疗法正在开发中。领先的机构正在研究修复老化 DNA 的方法，企业正在利用人工智能寻找能够停止或减缓老化的分子。</p>
<p>这些发现等使得美国食品药品监督管理局（FDA）和其他机构将老化归类为可治愈疾病。这一变化可能加快抗衰老药物的授权进程。</p>
<p>2021 年，全球抗衰老市场价值约为 620 亿美元，到 2027 年预计将达到 930 亿美元。</p>
<p>到 2025 年，60 岁以上的人口将增至 21 亿，随着生物技术的进步，如人工智能驱动的药物发现提供快速作用的抗衰老药物，长寿股将表现良好，这意味着现在是时候关注那些有超过 50% 上涨空间的三只长寿股了。</p>
<h2>Denali Therapeutics（DNLI）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Microgen / Shutterstock</p>
<p><strong>Denali Therapeutics</strong>（纳斯达克：<strong>DNLI</strong>）正在积极扩大其治疗前景组合，特别是针对穿越血脑屏障治疗神经退行性和溶酶体贮积疾病的药物。</p>
<p>DNL126 是一种用于治疗 MPS IIIA（常称为桑菲利波综合症 A 型）的研究性药物，可以穿越血脑屏障。Denali 正在进行其在 1/2 期的安全性、药代动力学和疗效测试。招募正在进行中，预计到 2024 年将产生生物标志物概念验证。</p>
<p>此外，针对 MPS II（亨特氏综合症），tividenofusp alfa 旨在将硫酸 2-硫酸酶运输穿越血脑屏障。FDA 已将其列为快速通道分类；欧洲药品管理局已将其分配为优先药物分类。Denali 正在招募欧洲、南美和北美等地区的受试者参加 2/3 期 Compass 试验。</p>
<p>DNL343 针对 ALS 并调节集成应激反应途径，该途径在 ALS 中过度活跃并导致神经元死亡。Denali 刚刚完成了其发展的一个重要阶段的招募，作为 HEALEY ALS 平台试验的一部分。</p>
<p>Denali 还在进行许多利用其运输车辆技术针对常见神经退行性疾病和溶酶体贮积疾病的临床前项目。IND 启动研究强调了使用 OTV 和 ATV 平台针对阿尔茨海默病和帕金森病的努力。</p>
<p>Denali Therapeutics 被评为 “强烈买入”。DNLI 的共识价格平均为 42.71 美元，反映了可能从其上次收盘价 21.14 美元上涨 102%。</p>
<h2>Geron（GERN）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Corona Borealis Studio / Shutterstock</p>
<p><strong>Geron Corp</strong>（纳斯达克：<strong>GERN</strong>）以其在血液恶性肿瘤中抑制端粒酶的创新工作而闻名，同时也在推进抗衰老研究，使其成为长寿股中不容错过的前景。</p>
<p>Geron 的关键药物 Imatetelstat 是一种新的端粒酶抑制剂，可以阻止骨髓性血液癌中癌干细胞和祖细胞的不受控制生长。目前，FDA 正在研究 Imatetelstat 是否可以作为治疗低风险骨髓增生异常综合征患者的依赖输血性贫血的可能疗法。到目前为止，结果看起来不错。Geron 还在研究如何利用它来帮助其他随年龄增长而出现的疾病，如骨髓纤维化。</p>
<p>欧盟官员也正在评估其营销授权申请。在 IMerge 第 3 期研究中，Imatetelstat 正在测试中度 2 或高风险 MF 以及 MDS。</p>
<p>Geron 通过端粒酶抑制研究抗衰老。该公司正在研究端粒酶抑制剂以延缓细胞老化和治疗与年龄相关的疾病，同时开发新的抗衰老药物。Geron 使用人工智能和机器学习来寻找摧毁这些细胞的小分子化合物。</p>
<p>GERN 被评为 “强烈买入”，平均价格目标为 7.07 美元，从 4.53 美元上涨 56%。</p>
<h2>Recursion Pharmaceuticals（RXRX）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Piotr Swat / Shutterstock.com</p>
<p><strong>Recursion Pharmaceuticals</strong>（纳斯达克：<strong>RXRX</strong>）与 Helix 基因组签订了为期多年的合同。这种关系使 Recursion 能够利用人工智能模型获得大规模临床基因组数据，促进制药开发和患者分层。这旨在加快为多种疾病，包括抗衰老疗法，开发精准药物。</p>
<p>在下载日活动中，Recursion 更新了其临床管线。公司预计 18 个月内多种药物的 2 期临床试验结果。</p>
<p>此外，公司在特定测试中预测化合物结果的成功率达到 90%，推进了其 ADME 和基因图谱技术。这些创新将使抗衰老药物更易于制造。</p>
<p>Recursion 还与 <strong>Nvidia</strong>（纳斯达克：<strong>NVDA</strong>）达成协议，利用人工智能和超级计算增强其研究。RXRX 使用 Nvidia 的 DGX 动力 BioHive-2 超级计算机处理大规模生物数据。Nvidia 对 Recursion 的 5000 万美元投资教会了人工智能系统更快、更准确地找到药物候选者。</p>
<p>Recursion 更新了价值 15 亿美元的 <strong>拜耳</strong>（OTCMKTS:<strong>BAYRY</strong>）合同，涵盖了七个癌症项目。该交易将利用 Recursion 的药物发现平台，该平台利用 Nvidia 的 BioHive-1 超级计算机探索复杂的生物和化学相互作用，以开发治愈癌症的药物。拜耳对 Recursion 的抗癌药物的承诺可能导致独家许可。</p>
<p>最后，Recursion 未来 12 个月的价格目标是 14 美元，比目前的 7.32 美元大幅增长超过 91%。</p>
<p><em>在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何持仓。</em></p>
<p><em>在发布日期，Faizan Farooque 在本文提到的证券中没有（直接或间接）任何持仓。本文所表达的观点属于作者个人，遵守 InvestorPlace.com 的发布指南。</em></p>
<p>Faizan Farooque 是 InvestorPlace.com 和许多其他金融网站的撰稿作者。Faizan 在分析股市方面有多年经验，并曾是标普全球市场情报的数据记者。他的热情是帮助普通投资者就其投资组合做出更明智的决策。</p>
<p>生物技术，医疗保健</p>
<p>成长股</p>

RXRX

<p>美国人口老龄化速度比以往任何时候都快，这导致人们对长寿股的兴趣增加。一些公司正在开发针对与年龄相关的基因组变化的治疗方法，并利用人工智能寻找能够减缓衰老的分子。这些进展可能会导致抗衰老药物的授权。预计到 2027 年，全球抗衰老市场价值将达到 930 亿美元。三家具有超过 50% 增长潜力的长寿股包括 Denali Therapeutics、Geron Corp 和 Recursion Pharmaceuticals</p>

<p>The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.</p>
<div class="lb-trans"><p>美国人口老龄化速度比以往任何时候都快，引起了对长寿股的兴趣。到 2030 年，五分之一的美国人将是老年人，而 100 年前这个比例是二十分之一。</p>
</div><p>As a result, Crispen-based treatments meant to target age-related genomic changes are in development. Leading organizations are looking at methods to fix aging DNA, and businesses are using artificial intelligence to find molecules that either halt or slow down aging.</p>
<div class="lb-trans"><p>因此，旨在针对与年龄相关的基因组变化的 Crispen 疗法正在开发中。领先的机构正在研究修复老化 DNA 的方法，企业正在利用人工智能寻找能够停止或减缓老化的分子。</p>
</div><p>These discoveries and more are enabling the FDA and other agencies to classify aging as a curable illness. This change might hasten the authorization of anti-aging medications.</p>
<div class="lb-trans"><p>这些发现等使得美国食品药品监督管理局（FDA）和其他机构将老化归类为可治愈疾病。这一变化可能加快抗衰老药物的授权进程。</p>
</div><p>The world anti-aging market was worth about $62 billion in 2021, and by 2027, it’s projected to be worth about $93 billion.</p>
<div class="lb-trans"><p>2021 年，全球抗衰老市场价值约为 620 亿美元，到 2027 年预计将达到 930 亿美元。</p>
</div><p>As the number of individuals more than 60 rises to 2.1 billion by 2025, longevity stocks will fare well as biotechnology advances like artificial intelligence-driven drug discovery provide fast-acting anti-aging drugs, which means it’s the right time to look at three longevity stocks with over 50% upside.</p>
<div class="lb-trans"><p>到 2025 年，60 岁以上的人口将增至 21 亿，随着生物技术的进步，如人工智能驱动的药物发现提供快速作用的抗衰老药物，长寿股将表现良好，这意味着现在是时候关注那些有超过 50% 上涨空间的三只长寿股了。</p>
</div><h2>Denali Therapeutics (DNLI)</h2>
<div class="lb-trans"><h2>Denali Therapeutics（DNLI）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Microgen / Shutterstock</p>
<div class="lb-trans"><p>来源：Microgen / Shutterstock</p>
</div><p><strong>Denali Therapeutics</strong>(NASDAQ:<strong>DNLI</strong>) is aggressively expanding its portfolio of therapeutic prospects, particularly when it comes to those developed to breach the blood-brain barrier for treating neurodegenerative and lysosomal storage disorders.</p>
<div class="lb-trans"><p><strong>Denali Therapeutics</strong>（纳斯达克：<strong>DNLI</strong>）正在积极扩大其治疗前景组合，特别是针对穿越血脑屏障治疗神经退行性和溶酶体贮积疾病的药物。</p>
</div><p>DNL126 is an investigational medication for MPS IIIA, commonly known as Sanfilippo syndrome Type A, that crosses the blood-brain barrier. Denali is testing its safety, pharmacokinetics, and efficacy in Phase 1/2. Recruitment is ongoing to produce biomarker proof of concept by 2024.</p>
<div class="lb-trans"><p>DNL126 是一种用于治疗 MPS IIIA（常称为桑菲利波综合症 A 型）的研究性药物，可以穿越血脑屏障。Denali 正在进行其在 1/2 期的安全性、药代动力学和疗效测试。招募正在进行中，预计到 2024 年将产生生物标志物概念验证。</p>
</div><p>In addition, targeting MPS II (Hunter syndrome), tividenofusp alfa seeks to transport iduronate 2-sulfatase across the blood-brain barrier. The FDA has given it Fast Track classification; the European Medicines Agency has assigned Priority Medicines classification. Denali is recruiting subjects for the Phase 2/3 Compass trial across Europe, South America, and North America among other areas.</p>
<div class="lb-trans"><p>此外，针对 MPS II（亨特氏综合症），tividenofusp alfa 旨在将硫酸 2-硫酸酶运输穿越血脑屏障。FDA 已将其列为快速通道分类；欧洲药品管理局已将其分配为优先药物分类。Denali 正在招募欧洲、南美和北美等地区的受试者参加 2/3 期 Compass 试验。</p>
</div><p>DNL343 targets ALS and regulates the integrated stress response pathway, which is hyperactive in ALS and causes neuronal death. Denali just finished enrollment for a major phase of its development, part of the HEALEY ALS Platform Trial.</p>
<div class="lb-trans"><p>DNL343 针对 ALS 并调节集成应激反应途径，该途径在 ALS 中过度活跃并导致神经元死亡。Denali 刚刚完成了其发展的一个重要阶段的招募，作为 HEALEY ALS 平台试验的一部分。</p>
</div><p>Denali is also working on many preclinical projects employing its Transport Vehicle technologies to target prevalent neurodegenerative illnesses and lysosomal storage disorders. IND-enabling research underlines efforts to target Alzheimer’s and Parkinson’s disease using the OTV and ATV platforms.</p>
<div class="lb-trans"><p>Denali 还在进行许多利用其运输车辆技术针对常见神经退行性疾病和溶酶体贮积疾病的临床前项目。IND 启动研究强调了使用 OTV 和 ATV 平台针对阿尔茨海默病和帕金森病的努力。</p>
</div><p>Denali Therapeutics is rated as a “Strong Buy.” DNLI’s consensus price is set at an average of $42.71, reflecting a possible rise of 102% from its last close of $21.14.</p>
<div class="lb-trans"><p>Denali Therapeutics 被评为 “强烈买入”。DNLI 的共识价格平均为 42.71 美元，反映了可能从其上次收盘价 21.14 美元上涨 102%。</p>
</div><h2>Geron (GERN)</h2>
<div class="lb-trans"><h2>Geron（GERN）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Corona Borealis Studio / Shutterstock</p>
<div class="lb-trans"><p>来源：Corona Borealis Studio / Shutterstock</p>
</div><p>Renowned for its innovative work on telomerase inhibition for blood malignancies, <strong>Geron Corp</strong>(NASDAQ: <strong>GERN</strong>) is also advancing anti-aging studies, making it a can’t-miss prospect among longevity stocks. Senescent cells, commonly known as “zombie cells,” secrete harmful compounds that kill surrounding healthy cells, causing aging and many age-related illnesses. The company has focused on treating them.</p>
<div class="lb-trans"><p><strong>Geron Corp</strong>（纳斯达克：<strong>GERN</strong>）以其在血液恶性肿瘤中抑制端粒酶的创新工作而闻名，同时也在推进抗衰老研究，使其成为长寿股中不容错过的前景。</p>
</div><p>Imatetelstat, Geron’s key drug, is a new telomerase inhibitor that stops the unchecked growth of cancerous stem and progenitor cells in myeloid blood cancers. At the moment, imetelstat is being looked at by the FDA as a possible treatment for transfusion-dependent anemia in people with lower-risk myelodysplastic syndromes. So far, the results look good. Geron is also looking into how it could be used to help other conditions that come with getting older, such as myelofibrosis.</p>
<div class="lb-trans"><p>Geron 的关键药物 Imatetelstat 是一种新的端粒酶抑制剂，可以阻止骨髓性血液癌中癌干细胞和祖细胞的不受控制生长。目前，FDA 正在研究 Imatetelstat 是否可以作为治疗低风险骨髓增生异常综合征患者的依赖输血性贫血的可能疗法。到目前为止，结果看起来不错。Geron 还在研究如何利用它来帮助其他随年龄增长而出现的疾病，如骨髓纤维化。</p>
</div><p>EU officials are also assessing its marketing authorization application. In the IMerge Phase 3 study, imetelstat is tested for intermediate-2 or high-risk MF as well as MDS.</p>
<div class="lb-trans"><p>欧盟官员也正在评估其营销授权申请。在 IMerge 第 3 期研究中，Imatetelstat 正在测试中度 2 或高风险 MF 以及 MDS。</p>
</div><p>Geron studies anti-aging via telomerase suppression. The company is studying telomerase inhibitors to delay cellular aging and treat age-related diseases while creating new anti-aging drugs. Geron uses AI and machine learning to locate small compounds that destroy these cells.</p>
<div class="lb-trans"><p>Geron 通过端粒酶抑制研究抗衰老。该公司正在研究端粒酶抑制剂以延缓细胞老化和治疗与年龄相关的疾病，同时开发新的抗衰老药物。Geron 使用人工智能和机器学习来寻找摧毁这些细胞的小分子化合物。</p>
</div><p>GERN is rated “Strong Buy,” and the average price target is $7.07, a potential upside of 56% from $4.53.</p>
<div class="lb-trans"><p>GERN 被评为 “强烈买入”，平均价格目标为 7.07 美元，从 4.53 美元上涨 56%。</p>
</div><h2>Recursion Pharmaceuticals (RXRX)</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals（RXRX）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Piotr Swat / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Piotr Swat / Shutterstock.com</p>
</div><p><strong>Recursion Pharmaceuticals</strong> (NASDAQ: <strong>RXRX</strong>) has a multi-year Helix genomics contract. This relationship gives Recursion access to large-scale clinico-genomic data using AI models, boosting pharmaceutical development and patient stratification. This is meant to speed up the development of precision drugs for numerous diseases, including anti-aging therapy.</p>
<div class="lb-trans"><p><strong>Recursion Pharmaceuticals</strong>（纳斯达克：<strong>RXRX</strong>）与 Helix 基因组签订了为期多年的合同。这种关系使 Recursion 能够利用人工智能模型获得大规模临床基因组数据，促进制药开发和患者分层。这旨在加快为多种疾病，包括抗衰老疗法，开发精准药物。</p>
</div><p>At Download Day, Recursion updated its clinical pipeline. The company anticipates Phase 2 clinical trial findings for multiple drugs in 18 months.</p>
<div class="lb-trans"><p>在下载日活动中，Recursion 更新了其临床管线。公司预计 18 个月内多种药物的 2 期临床试验结果。</p>
</div><p>What’s more, using a 90% success rate in forecasting compound outcomes in specific tests, the company has advanced its ADME and genetic mapping techniques. These innovations would make anti-aging drugs easier to make.</p>
<div class="lb-trans"><p>此外，公司在特定测试中预测化合物结果的成功率达到 90%，推进了其 ADME 和基因图谱技术。这些创新将使抗衰老药物更易于制造。</p>
</div><p>Recursion also has a deal with <strong>Nvidia</strong>(NASDAQ:<strong>NVDA</strong>) to enhance its research with AI and supercomputing. RXRX uses Nvidia’s DGX-powered BioHive-2 supercomputer to handle massive biological data. The $50 million Nvidia investment in Recursion teaches AI systems to find pharmaceutical candidates faster and more accurately.</p>
<div class="lb-trans"><p>Recursion 还与 <strong>Nvidia</strong>（纳斯达克：<strong>NVDA</strong>）达成协议，利用人工智能和超级计算增强其研究。RXRX 使用 Nvidia 的 DGX 动力 BioHive-2 超级计算机处理大规模生物数据。Nvidia 对 Recursion 的 5000 万美元投资教会了人工智能系统更快、更准确地找到药物候选者。</p>
</div><p>Recursion’s updated $1.5 billion <strong>Bayer</strong>(OTCMKTS:<strong>BAYRY</strong>) contract covers seven cancer projects. This deal will use Recursion’s drug discovery platform, which uses Nvidia’s BioHive-1 supercomputer to explore complicated biological and chemical interactions to develop cancer cures. Bayer’s commitment to Recursion’s cancer drugs may lead to exclusive licensing.</p>
<div class="lb-trans"><p>Recursion 更新了价值 15 亿美元的 <strong>拜耳</strong>（OTCMKTS:<strong>BAYRY</strong>）合同，涵盖了七个癌症项目。该交易将利用 Recursion 的药物发现平台，该平台利用 Nvidia 的 BioHive-1 超级计算机探索复杂的生物和化学相互作用，以开发治愈癌症的药物。拜耳对 Recursion 的抗癌药物的承诺可能导致独家许可。</p>
</div><p>Last but not least, Recursion’s price goal for the next 12 months is $14, which is a huge increase of over 91% from its current price of $7.32.</p>
<div class="lb-trans"><p>最后，Recursion 未来 12 个月的价格目标是 14 美元，比目前的 7.32 美元大幅增长超过 91%。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何持仓。</em></p>
</div><p><em>On the date of publication, Faizan Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p><em>在发布日期，Faizan Farooque 在本文提到的证券中没有（直接或间接）任何持仓。本文所表达的观点属于作者个人，遵守 InvestorPlace.com 的发布指南。</em></p>
</div><p>Faizan Farooque is a contributing author for InvestorPlace.com and numerous other financial sites. Faizan has several years of experience in analyzing the stock market and was a former data journalist at S&amp;P Global Market Intelligence. His passion is to help the average investor make more informed decisions regarding their portfolio.</p>
<div class="lb-trans"><p>Faizan Farooque 是 InvestorPlace.com 和许多其他金融网站的撰稿作者。Faizan 在分析股市方面有多年经验，并曾是标普全球市场情报的数据记者。他的热情是帮助普通投资者就其投资组合做出更明智的决策。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物技术，医疗保健</p>
</div><p>Growth Stocks</p>
<div class="lb-trans"><p>成长股</p>
</div>

3 只抗衰老突破的长寿股票